Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Effects of vardenafil administration on intravaginal ejaculatory latency time in men with lifelong premature ejaculation

International Journal of Impotence Research volume 21, pages 221–227 (2009)Cite this article

Abstract

Premature ejaculation (PE) is thought to be the most common male sexual dysfunction; however, the prevalence of lifelong (LL)-PE is relatively low. The aim of this study was to investigate the effects of on-demand vardenafil (10 mg) to modify the intravaginal ejaculatory latency time (IELT) in men with LL-PE without erectile dysfunction. Forty-two men (18–35 years) were enrolled in a 16-week, double-blind, placebo-controlled, cross-over study. Primary end point was the modification from baseline of IELT assessed by stopwatch technique; secondary end points were post-ejaculatory refractory time (PERT) and variations of scores at the Index of Premature Ejaculation questionnaire. The changes in geometric mean IELT were superior after taking vardenafil (0.6±0.3 vs 4.5±1.1 min, P<0.01), compared with placebo (0.7±0.3 vs 0.9±1.0 min, ns). PERT dropped significantly after vardenafil (16.7±2.0 vs 4.3±0.9 min, P<0.001), compared with placebo (15.3±2.2 vs 15.8±2.3 min). Patients who took vardenafil (vs placebo) reported significantly (P<0.01) increased ejaculatory control (6±2 vs 16±2), improved overall sexual satisfaction (7±2 vs 15±1) and distress (4±1 vs 8±1) scores, respectively. Multiple regression analysis (r2=0.86) for IELT by the number of attempts at sexual intercourse showed significant differences between the slopes of lines for placebo and vardenafil (P<0.0001). The most common adverse events for vardenafil (vs placebo) were headache (10 vs 3%), flushing (12 vs 0%) and dyspepsia (10 vs 0%), which tended to disappear over the time. In conclusion, in our study, vardenafil increased IELT and reduced PERT in men with LL-PE. Besides, improvements in confidence, perception of ejaculatory control and overall sexual satisfaction were reported.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

References

  1. Porst H, Montorsi F, Rosen RC, Gaynor L, Grupe S, Alexander J . The Premature Ejaculation Prevalence and Attitudes (PEPA) survey: prevalence, comorbidities, and professional help-seeking. Eur Urol 2007; 51: 816–823.

    Article  Google Scholar 

  2. Waldinger MD, Zwinderman AH, Olivier B, Schweitzer DH . Proposal for a definition of lifelong premature ejaculation based on epidemiological stopwatch data. J Sex Med 2005; 2: 498–507.

    Article  Google Scholar 

  3. McMahon CG, Althof S, Waldinger MD, Porst H, Dean J, Sharlip I et al., International Society for Sexual Medicine Ad Hoc Committee for Definition of Premature Ejaculation. An evidence-based definition of lifelong premature ejaculation: report of the International Society for Sexual Medicine Ad Hoc Committee for the Definition of Premature Ejaculation. BJU Int 2008; 102: 338–350.

    Article  Google Scholar 

  4. Waldinger MD, Schweitzer DH . The use of old and recent DSM definitions of premature ejaculation in observational studies: a contribution to the present debate for a new classification of PE in the DSM-V. J Sex Med 2008; 5: 1079–1087.

    Article  Google Scholar 

  5. Waldinger MD . Lifelong premature ejaculation: from authority-based to evidence-based medicine. BJU Int 2004; 93: 201–207.

    Article  CAS  Google Scholar 

  6. Waldinger MD, Zwinderman AH, Schweitzer DH, Olivier B . Relevance of methodological design for the interpretation of efficacy of drug treatment of premature ejaculation: a systematic review and meta-analysis. Int J Impot Res 2004; 16: 369–381.

    Article  CAS  Google Scholar 

  7. Mathers MJ, Klotz T, Roth S, Lümmen G, Sommer F . Safety and efficacy of vardenafil versus sertraline in the treatment of premature ejaculation: a randomised, prospective and crossover study. Andrologia 2009; 41: 169–175.

    Article  CAS  Google Scholar 

  8. Aversa A, Mazzilli F, Rossi T, Delfino M, Isidori AM, Fabbri A . Effects of sildenafil (Viagra) administration on seminal parameters and post-ejaculatory refractory time in normal males. Hum Reprod 2000; 15: 131–134.

    Article  CAS  Google Scholar 

  9. Mondaini N, Ponchietti R, Muir GH, Montorsi F, Di Loro F, Lombardi G et al. Sildenafil does not improve sexual function in men without erectile dysfunction but does reduce the post-orgasmic refractory time. Int J Impot Res 2003; 15: 225–228.

    Article  CAS  Google Scholar 

  10. Althof S, Rosen R, Symonds T, Mundayat R, May K, Abraham L . Development and validation of new questionnaire to assess sexual satisfaction, control, and distress associated with premature ejaculation. J Sex Med 2006; 3: 465–475.

    Article  Google Scholar 

  11. Symonds T, Perelman MA, Althof S, Giuliano F, Martin M, May K et al. Development and validation of a premature ejaculation diagnostic tool. Eur Urol 2007; 52: 565–573.

    Article  Google Scholar 

  12. Cappelleri JC, Rosen RC, Smith MD, Mishra A, Osterloh IH . Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function. Urology 1999; 54: 346–351.

    Article  CAS  Google Scholar 

  13. Waldinger MD, Zwinderman AH, Olivier B, Schweitzer DH . Geometric mean IELT and premature ejaculation: appropriate statistics to avoid overestimation of treatment efficacy. J Sex Med 2008; 5: 492–499.

    Article  Google Scholar 

  14. Chen J, Keren-Paz G, Bar-Yosef Y, Matzkin H . The role of phosphodiesterase type 5 inhibitors in the management of premature ejaculation: a critical analysis of basic science and clinical data. Eur Urol 2007; 52: 1331–1339.

    Article  Google Scholar 

  15. Chen J, Mabjeesh NJ, Matzkin H, Greenstein A . Efficacy of sildenafil as adjuvant therapy to selective serotonin reuptake inhibitor in alleviating premature ejaculation. Urology 2003; 61: 197–200.

    Article  Google Scholar 

  16. McMahon CG, Stuckey BGA, Andersen M, Purvis K, Koppiker N, Haughie S et al. Efficacy of Sildenafil Citrate (Viagra) in men with premature ejaculation. J Sex Med 2005; 2: 368–375.

    Article  CAS  Google Scholar 

  17. Salonia A, Maga T, Colombo R, Scattoni V, Briganti A, Cestari A et al. A prospective study comparing paroxetine alone versus paroxetine plus sildenafil in patients with premature ejaculation. J Urol 2002; 168: 2486–2489.

    Article  CAS  Google Scholar 

  18. Wang WF, Wang Y, Minhas S, Ralph DJ . Can sildenafil treat primary premature ejaculation? A prospective clinical study. Int J Urol 2007; 14: 331–335.

    Article  CAS  Google Scholar 

  19. Rowland DL, Motofei IG . The aetiology of premature ejaculation and the mind-body problem: implications for practice. Int J Clin Pract 2007; 61: 77–82.

    Article  CAS  Google Scholar 

  20. Pfaus JG . Neurobiology of sexual behavior. Curr Opin Neurobiol 1999; 9: 751–758.

    Article  CAS  Google Scholar 

  21. Prickaerts J, van Staveren WC, Sik A, Markerink-van Ittersum M, Niewöhner U, van der Staay FJ et al. Effects of two selective phosphodiesterase type 5 inhibitors, sildenafil and vardenafil, on object recognition memory and hippocampal cyclic GMP levels in the rat. Neuroscience 2002; 113: 351–361.

    Article  CAS  Google Scholar 

  22. Castellano M, Rizzoni D, Beschi M, Muiesan ML, Porteri E, Bettoni G et al. Relationship between sympathetic nervous system activity, baroreflex and cardiovascular effects after acute nitric oxide synthesis inhibition in humans. J Hypertens 1995; 13: 1153–1161.

    Article  CAS  Google Scholar 

  23. Krukoff TL . Central regulation of autonomic function: no brakes? Clin Exp Pharmacol Physiol 1998; 25: 474–478.

    Article  CAS  Google Scholar 

  24. Uckert S, Bazrafshan S, Scheller F, Mayer ME, Jonas U, Stief CG . Functional responses of isolated human seminal vesicle tissue to selective phosphodiesterase inhibitors. Urology 2007; 70: 185–189.

    Article  Google Scholar 

  25. Uckert S, Bazrafshan S, Sonnenberg JE, Kuczyk ME . Effects of phosphodiesterase inhibitors on the contractile responses of isolated human seminal vesicle tissue to adrenergic stimulation. J Sex Med 2009; 6: 408–414.

    Article  Google Scholar 

  26. Uckert S, Sormes M, Kedia G, Scheller F, Knapp WH, Jonas U et al. Effects of phosphodiesterase inhibitors on tension induced by norepinephrine and accumulation of cyclic nucleotides in isolated human prostatic tissue. Urology 2008; 71: 526–530.

    Article  Google Scholar 

  27. Kriegsfeld LJ, Demas GE, Huang PL, Burnett AL, Nelson RJ . Ejaculatory abnormalities in mice lacking the gene for endothelial nitric oxide synthase (eNOS−/−). Physiol Behav 1999; 67: 561–566.

    Article  CAS  Google Scholar 

  28. Teixeira CE, Priviero FB, Webb RC . Differential effects of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, and tadalafil in rat aorta. J Pharmacol Exp Ther 2006; 316: 654–661.

    Article  CAS  Google Scholar 

  29. Toque HA, Teixeira CE, Priviero FB, Morganti RP, Antunes E, De Nucci G . Vardenafil, but not sildenafil or tadalafil, has calcium-channel blocking activity in rabbit isolated pulmonary artery and human washed platelets. Br J Pharmacol 2008; 154: 787–796.

    Article  CAS  Google Scholar 

  30. Waldinger MD, Zwinderman AH, Olivier B, Schweitzer DH . The majority of men with lifelong premature ejaculation prefer daily drug treatment: an observation study in a consecutive group of Dutch men. J Sex Med 2007; 4: 1028–1037.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Chair of Internal Medicine, DFM, Sapienza University of Rome, Italy

    A Aversa, M Pili, D Francomano, R Bruzziches & G Spera

  2. Urology Department, Tor Vergata University of Rome, Italy

    E Spera

  3. Azienda Ospedaliera San Camillo, Forlanini, Rome, Italy

    G La Pera

Authors
  1. A Aversa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Pili
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D Francomano
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R Bruzziches
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E Spera
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G La Pera
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G Spera
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A Aversa.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Aversa, A., Pili, M., Francomano, D. et al. Effects of vardenafil administration on intravaginal ejaculatory latency time in men with lifelong premature ejaculation. Int J Impot Res 21, 221–227 (2009). https://doi.org/10.1038/ijir.2009.21

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ijir.2009.21

Keywords

  • phosphodiesterase type-5 inhibitor
  • IELT
  • PERT
  • ejaculatory control
  • treatment

This article is cited by

Search

Advanced search

Quick links